Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Health care providers say that hesitation and outright resistance to vaccines have become disturbingly common even in ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case ... expected quarterly loss of $2.91 per share, compared to ...

Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...

Moderna MRNA ... 2024 compared with $2.8 billion in the year-ago quarter. Per management, the decrease was primarily due to the earlier launch of the updated COVID-19 vaccine in the United States ...

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...

The UK has become the first country in the world to authorise an updated COVID-19 booster ... Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS ...

Moderna CEO Stéphane ... and flu-COVID combination vaccines, with PDUFA dates set for mid-2025. The company projects 2025 revenue within $1.5 billion to $2.5 billion, influenced by uncertainties ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss ... including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...